

## Solid Q3 product sales growth: +21%

- Strong growth from direct sales channels in France and the USA
  - On-going positive momentum in China

Aix-en-Provence, France, October 20, 2015 – SuperSonic Imagine (Euronext: SSI, FR0010526814, PEA-PME eligible), a company specializing in ultrasound medical imaging, today announces its revenue for the 3<sup>rd</sup> quarter ended September 30, 2015.

<i>In thousands of euros</i>	2015	2014	Δ
Products	2,861	2,612	+10%
Services	371	309	+20%
<b>Q1 sales</b>	<b>3,232</b>	<b>2,921</b>	<b>+11%</b>
Products	4,579	4,788	-4%
Services	440	410	+7%
<b>Q2 sales</b>	<b>5,019</b>	<b>5,198</b>	<b>-3%</b>
Products	4,759	3,924	+21%
Services	440	505	-13%
<b>Q3 sales</b>	<b>5,199</b>	<b>4,429</b>	<b>+17%</b>
Products	12,199	11,324	+8%
Services	1,251	1,224	+2%
<b>9-month sales (to 30/09/2015)</b>	<b>13,450</b>	<b>12,547</b>	<b>+7%</b>
Other revenue	1,278	1,097	+16%
<b>Total 9-month revenue</b>	<b>14,728</b>	<b>13,644</b>	<b>+8%</b>

*Unaudited data*

Due to the strong performance of the direct sales force in the United States and France, validating the applicability of the Company's new sales strategy, SuperSonic Imagine recorded in Q3 2015 a +17% increase in total sales to €5.2m (vs. €4.4m), driven by a +21% growth in sales of Aixplorer products to €4.8m. Sales of Services, was at a level of €440k (vs. €505k) and accounted for 8% of total sales over the quarter. At constant currency, sales growth was +10% for the quarter.

Over the quarter, the Company recorded a favorable performance in EMEA and Asia, with growth of +34% to €2.3m and +21% to €1.6m respectively, driven by the positive dynamic of these markets' growth engines - France and China. The strong performance of direct sales in USA almost compensated for the decline in indirect sales after the termination by the company of its exclusive distribution partnership in the United States. Therefore sales in Americas were €1.3m (compared to €1.4m last year when the distributor was still fully active).

As of September 30, 2015, SuperSonic Imagine had an installed base of 1,239 Aixplorer systems worldwide, with a split of 28% in the Americas, 45% in EMEA and 27% in Asia.

Other revenue, which essentially consists of access fees to the Group's technology, is a non recurrent event and totaled €1.3m (vs. €1.1m) as of September 30, 2015.

Tom Egelund, SuperSonic Imagine's CEO, comments: "We are pleased with the sales recorded over this third quarter on all of our priority markets, and notably in the United States where the direct

*sales team recently established recorded a good performance. Our French direct sales team also delivered a strong performance, more than doubling sales growth. Finally, our sales organization in China continued to build on the momentum seen in previous quarters. These performances highlight not only the continuing adoption of our technology, but also and more importantly, the value of our sales strategy that has been redefined around market access by specialty, particularly in Breast and Liver. This new strategy allows us to clearly demonstrate to our customers Aixplorer's strong clinical benefits as illustrated by novel peer reviewed publications<sup>1</sup> and increase its adoption. We are reaping the initial rewards of the intense efforts undertaken to return to a rate of growth in line with our ambitions as quickly as possible, and we have confidence in our continued growth trajectory."*

**Next press release:** 2015 annual revenue, on January 19, 2016

### **About SuperSonic Imagine**

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer<sup>®</sup>, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer<sup>®</sup> is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer<sup>®</sup> in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to [www.supersonicimagine.com](http://www.supersonicimagine.com)

#### **SuperSonic Imagine**

Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
+33 4 86 79 03 27

#### **NewCap**

Investor Relations - EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

#### **Blueprint Life Science Group**

Investor Relations - US  
Candice Knoll  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
+1 415 375 3340 Ext. #4

#### **ComCorp**

Media Relations  
Adelaïde Manester  
[amanester@comcorp.fr](mailto:amanester@comcorp.fr)  
+33 1 58 18 32 58



---

<sup>1</sup> Quantitative Maximum Shear-Wave Stiffness of Breast Masses as a Predictor of Histopathologic Severity. Berg WA, et al. AJR Am J Roentgenol. 2015 Aug;205(2):448-55.

Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices. Cassinotto C, et al. Dig Liver Dis. 2015 Aug;47(8):695-701.